Zepbound, developed by Eli Lilly, is an FDA-approved injectable medication designed for chronic weight management in adults with obesity (BMI ≥ 30) or overweight individuals (BMI ≥ 27) with at least one weight-related condition, such as type 2 diabetes or high blood pressure. The active ingredient in Zepbound, tirzepatide, works by activating the body’s GLP-1 and GIP receptors, which helps reduce appetite and food intake.
Zepbound is administered via a weekly injection, with doses ranging from 2.5 mg to 15 mg. Clinical trials, such as the SURMOUNT studies, demonstrated its significant effectiveness in weight reduction. In these trials, participants who used the highest dose (15 mg) lost up to 18% of their body weight after 72 weeks.
Email: info@allmedistore.com
